Summary

The antibody therapeutics market is projected to reach USD 597.1 billion by 2035, up from USD 311.2 billion in 2026, at a CAGR of 7.5% over the forecast period. Market growth is driven by increasing demand for highly targeted biologic therapies across oncology, autoimmune diseases, inflammatory disorders, and other chronic conditions. Monoclonal antibodies remain a major contributor to growth. Advances in antibody engineering are also expanding the market beyond conventional monoclonal antibodies to include bispecific and multispecific antibodies, antibody fragments, and antibody-drug conjugates (ADCs).

By product, the commercialized antibody therapeutics market segment accounted for the largest share of the market in 2025.

The market is segmented into commercialized products (Keytruda, Dupixent, Skyrizi, Darzalex, Vyvgart, and other commercialized products) and pipeline products (Ivonescimab, Sacituzumab tirumotecan (Sac-TMT), Izalontamab brengitecan, and other pipeline products). In 2025, the commercialized antibody therapeutics segment accounted for the largest share of the market, driven by strong clinical adoption and revenue contributions from approved monoclonal antibodies, immune checkpoint inhibitors, anti-inflammatory biologics, ADCs, and bispecific antibodies. This dominance reflects the proven efficacy, target specificity, established safety profiles, and broad use of these therapies across oncology, autoimmune, inflammatory, hematologic, ophthalmic, and rare disease indications.

In 2025, North America accounted for the largest share of the overall antibody therapeutics market.

The US is the largest contributor to North America’s antibody therapeutics market, supported by a dense ecosystem of leading biopharmaceutical companies, academic medical centers, research institutes, clinical-trial networks, and specialized biologics manufacturers. The region benefits from high healthcare spending, strong funding for biologics R&D, early adoption of targeted therapies, and established regulatory pathways that support the development and commercialization of monoclonal antibodies, bispecific antibodies, ADCs, and other next-generation antibody formats.

The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
- By Designation: C-level Executives - 30%, Directors- 45%, and Others- 25%
- By Region: North America - 35%, Europe - 25%, Asia Pacific - 15%, Latin America - 10%, Middle East- 10%, and Africa - 5%

AbbVie Inc. (US), Merck (US), Novartis AG (Switzerland), Bristol-Myers Squibb (US), Johnson & Johnson (US), F. Hoffmann-La Roche Ltd. (Switzerland), Regeneron Pharmaceuticals Inc. (US), Boehringer Ingelheim International GmbH (Germany), MacroGenics, Inc. (US), Sanofi (France), Amgen Inc. (US), GlaxoSmithKline plc (UK), Eli Lilly and Company (US), Pfizer Inc. (US), Daiichi Sankyo, Inc. (Japan), AstraZeneca (UK), Celltrion (South Korea), UCB, Inc. (Belgium), Innovent Biologics (China), Emergent BioSolutions Inc. (US), Immunocore Ltd. (UK).

Research Coverage:
This research report categorizes antibody therapeutics market by product (commercialized products, pipeline products), format (monoclonal antibodies, polyclonal antibodies, antibody fragments, bispecific antibodies, antibody drug conjugates), target (PD-1/PD-L1, TNF alpha, cytokine/inflammatory pathway targets, HER2, other targets), source (human, humanized, chimeric, other sources), route of administration (intravenous, subcutaneous, other routes of administration), therapeutic area (autoimmune & inflammatory diseases, oncology, hematology, infectious diseases, osteology, immunology, neurology, other therapeutic areas), end user (hospitals & specialty care centers, long-term care facilities, other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report's scope covers detailed information on the primary factors, such as drivers, restraints, challenges, and opportunities, that influence the growth of the antibody therapeutics market. A thorough analysis of key industry players has been conducted to provide insights into their business overviews, products, key strategies, new product launches, acquisitions, and recent developments associated with the antibody therapeutics market. This report also covers the competitive analysis of upcoming startups in the antibody therapeutics market ecosystem.

Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing the closest approximations of revenue for the antibody therapeutics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their business and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights into the following:
- Analysis of key drivers (strong approval and pipeline momentum), restraints (long, capital-intensive development), opportunities (expansion beyond oncology), and challenges (safety and post-approval obligations) influencing the growth of the antibody therapeutics market
- Product Approvals: Detailed insights on newly approved products of the antibody therapeutics market
- Market Development: Comprehensive information about lucrative markets – the report analyzes the antibody therapeutics market across varied regions
- Market Diversification: Exhaustive information about new products, recent developments, and investments in the antibody therapeutics market
- Pipeline Analysis: Comprehensive information about antibody therapeutics under clinical trials
- Competitive Assessment: In-depth assessment of market, growth strategies, and product offerings of leading players, including AbbVie Inc. (US), Merck (US), Johnson & Johnson (US), Regeneron Pharmaceuticals Inc. (US), Sanofi (France), Amgen Inc. (US), GlaxoSmithKline plc (UK), among several others, are key players in the antibody therapeutics market

ページTOPに戻る

Table of Contents

1 INTRODUCTION 46
1.1 STUDY OBJECTIVES 46
1.2 MARKET DEFINITION 46
1.3 STUDY SCOPE 46
1.3.1 MARKET SEGMENTATION & REGIONS COVERED 47
1.3.2 INCLUSIONS & EXCLUSIONS 48
1.3.3 YEARS CONSIDERED 48
1.3.4 CURRENCY CONSIDERED 49
1.4 STAKEHOLDERS 49
1.5 SUMMARY OF CHANGES 49

2 EXECUTIVE SUMMARY 51
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 51
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 52
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 53
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 54
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 55

3 PREMIUM INSIGHTS 56
3.1 ANTIBODY THERAPEUTICS MARKET OVERVIEW 56
3.2 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION & REGION 57
3.3 ANTIBODY THERAPEUTICS MARKET: GEOGRAPHIC SNAPSHOT 58
3.4 ANTIBODY THERAPEUTICS MARKET SHARE, BY SOURCE, 2026 VS. 2035 (%) 58

4 MARKET OVERVIEW 59
4.1 INTRODUCTION 59
4.2 MARKET DYNAMICS 59
4.2.1 DRIVERS 60
4.2.1.1 Rising clinical success and regulatory approvals of antibody therapeutics 60
4.2.1.2 Technological advancements in antibody engineering and bispecific platforms 61
4.2.2 RESTRAINTS 61
4.2.2.1 Patent expirations and biosimilar competition intensifying pricing pressure 61
4.2.3 OPPORTUNITIES 62
4.2.3.1 Expansion of antibody therapeutics into non-oncology therapeutic areas 62
4.2.3.2 Rapid expansion of bispecific and multispecific antibody platforms 62
4.2.4 CHALLENGES 62
4.2.4.1 Concerns related to biocompatibility, safety, and adverse immune responses 62
4.3 UNMET NEEDS & WHITE SPACES 63
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 63
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 64

5 INDUSTRY TRENDS 65
5.1 PORTER’S FIVE FORCES ANALYSIS 65
5.1.1 THREAT OF NEW ENTRANTS 66
5.1.2 THREAT OF SUBSTITUTES 66
5.1.3 BARGAINING POWER OF BUYERS 66
5.1.4 BARGAINING POWER OF SUPPLIERS 66
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 67
5.2 MACROECONOMIC OUTLOOK 67
5.2.1 INTRODUCTION 67
5.2.2 GDP TRENDS & FORECAST 68
5.2.3 TRENDS IN GLOBAL ANTIBODY THERAPEUTICS MARKET 68
5.3 VALUE CHAIN ANALYSIS 69
5.4 ECOSYSTEM ANALYSIS 70
5.4.1 LIST OF KEY ANTIBODY CDMOS/CMOS & SERVICE PROVIDERS 71
5.4.2 MANUFACTURING SITES & CAPACITY EXPANSION OF KEY ANTIBODY MANUFACTURERS 72
5.5 PRICING ANALYSIS 72
5.5.1 AVERAGE SELLING PRICE OF KEY PRODUCTS, BY KEY PLAYER (2025) 73
5.5.2 INDICATIVE PRICING ANALYSIS, BY PRODUCT (2023–2025) 73
5.5.3 AVERAGE SELLING PRICE OF KEY PRODUCTS, BY REGION (2025) 74
5.6 KEY CONFERENCES & EVENTS, 2026–2027 74
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75
5.8 INVESTMENT/FUNDING ACTIVITY 75
5.9 IMPACT OF 2025 US TARIFFS ON GLOBAL ANTIBODY THERAPEUTICS MARKET 76
5.9.1 INTRODUCTION 76
5.9.2 PRICE IMPACT ANALYSIS 77
5.9.3 IMPACT ON COUNTRY/REGION 77
5.9.3.1 North America 77
5.9.3.2 Europe 78
5.9.3.3 Asia Pacific 78
5.9.4 IMPACT ON END-USE INDUSTRIES 79
5.9.4.1 Hospitals 79
5.9.4.2 Specialty clinics & cancer centers 79
5.9.4.3 Other specialty care settings 79

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS,
AND FUTURE APPLICATIONS 80
6.1 INTRODUCTION 80
6.2 KEY EMERGING TECHNOLOGIES 80
6.2.1 BISPECIFIC & MULTISPECIFIC ANTIBODY ENGINEERING 80
6.2.2 NEXT-GENERATION ANTIBODY–DRUG CONJUGATES (ADCS) 80
6.2.3 FC ENGINEERING & HALF-LIFE EXTENSION 81
6.3 ADJACENT TECHNOLOGIES 81
6.3.1 ANTIBODY DISCOVERY & ENGINEERING PLATFORMS 81
6.3.2 GLYCOENGINEERING & EXPRESSION-SYSTEM ENGINEERING 82
6.4 COMPLEMENTARY TECHNOLOGIES 82
6.4.1 SUBCUTANEOUS DELIVERY & CO-FORMULATION 82
6.4.2 COMPANION DIAGNOSTICS & BIOMARKER-GUIDED PATIENT SELECTION 82
6.5 TECHNOLOGY/PRODUCT ROADMAP 83
6.6 FUTURE APPLICATIONS 83
6.7 PIPELINE ANALYSIS 83
6.7.1 KEY PIPELINE PRODUCTS & INDICATION EXPANSION 84
6.7.2 DISCONTINUED/DEPRIORITIZED PIPELINE ASSETS 85
6.8 IMPACT OF AI/GEN AI ON GLOBAL ANTIBODY THERAPEUTICS MARKET 86
6.8.1 TOP USE CASES & MARKET POTENTIAL 87
6.8.2 CASE STUDIES OF AI IMPLEMENTATION IN GLOBAL ANTIBODY THERAPEUTICS MARKET 87
6.8.3 INTERCONNECTED ADJACENT ECOSYSTEM & IMPACT ON MARKET PLAYERS 88
6.8.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN GLOBAL ANTIBODY THERAPEUTICS MARKET 88

7 SUSTAINABILITY & REGULATORY LANDSCAPE 89
7.1 REGIONAL REGULATIONS & COMPLIANCE 89
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
7.1.2 REGULATORY FRAMEWORK & REIMBURSEMENT 93
7.1.3 INDUSTRY STANDARDS 96
7.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 97
7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 98

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 99
8.1 DECISION-MAKING PROCESS 99
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 100
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 100
8.2.2 KEY BUYING CRITERIA, BY END USER 100
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 102
8.4 UNMET NEEDS FROM END USERS 102
8.5 MARKET PROFITABILITY 103

9 ANTIBODY THERAPEUTICS MARKET, BY PRODUCT 104
9.1 INTRODUCTION 105
9.2 COMMERCIALIZED PRODUCTS 105
9.2.1 KEYTRUDA 109
9.2.1.1 Earlier-stage use, combination regimens, and subcutaneous conversion to sustain Keytruda leadership 109
9.2.2 DUPIXENT 113
9.2.2.1 Expansion across type 2 inflammatory diseases and age groups to support continued Dupixent growth 113
9.2.3 SKYRIZI 116
9.2.3.1 Durable IL-23 efficacy and gastroenterology expansion to reinforce Skyrizi adoption 116
9.2.4 DARZALEX 119
9.2.4.1 Frontline combinations and rapid subcutaneous dosing to extend Darzalex franchise 119
9.2.5 VYVGART 122
9.2.5.1 FcRn class expansion and self-administered delivery to accelerate Vyvgart uptake 122
9.2.6 OTHER COMMERCIALIZED PRODUCTS 125
9.3 PIPELINE PRODUCTS 128
9.3.1 IVONESCIMAB 132
9.3.1.1 Dual PD-1/VEGF blockade and broad Phase III development to support Ivonescimab’s global potential 132
9.3.2 SACITUZUMAB TIRUMOTECAN (SAC-TMT) 135
9.3.2.1 TROP2 validation and topoisomerase-I payload activity to drive sac-TMT across solid tumors 135
9.3.3 IZALONTAMAB BRENGITECAN 138
9.3.3.1 Dual EGFR/HER3 targeting and ADC delivery to support iza-bren in resistant epithelial cancers 138
9.3.4 OTHER PIPELINE PRODUCTS 141

10 ANTIBODY THERAPEUTICS MARKET, BY FORMAT 144
10.1 INTRODUCTION 145
10.2 MONOCLONAL ANTIBODIES 145
10.2.1 BROAD CLINICAL VALIDATION AND REPEATED INDICATION EXPANSION TO MAKE MONOCLONAL ANTIBODIES LARGEST FORMAT 145
10.3 POLYCLONAL ANTIBODIES 149
10.3.1 EMERGENCY PREPAREDNESS AND SPECIALIST USE TO SUSTAIN DEMAND FOR POLYCLONAL ANTIBODIES 149
10.4 ANTIBODY FRAGMENTS 152
10.4.1 IMPROVED TISSUE PENETRATION AND LOCAL DELIVERY TO SUPPORT GROWTH OF ANTIBODY FRAGMENTS 152
10.5 BISPECIFIC ANTIBODIES 155
10.5.1 RAPID APPROVALS AND DUAL-TARGET MECHANISMS TO MAKE BISPECIFIC ANTIBODIES HIGH-GROWTH FORMAT 155
10.6 ANTIBODY-DRUG CONJUGATES (ADCS) 158
10.6.1 DM1 161
10.6.1.1 Established HER2 use and regional follow-on products to sustain the DM1 payload segment 161
10.6.2 MMAE 164
10.6.2.1 Broad target applicability and large approved product base to support MMAE growth 164
10.6.3 SN-38 168
10.6.3.1 TROP-2 validation and bystander activity to support continued
SN-38 demand 168
10.6.4 DM4 171
10.6.4.1 Folate receptor-alpha-based patient selection to anchor DM4 payload segment 171
10.6.5 OTHER PAYLOAD TYPES 174
10.7 OTHER ANTIBODY THERAPEUTICS 177

11 ANTIBODY THERAPEUTICS MARKET, BY TARGET 180
11.1 INTRODUCTION 181
11.2 PD-1/PD-L1 181
11.2.1 BROAD ONCOLOGY USE AND COMBINATION STRATEGIES TO SUSTAIN PD-1/PD-L1 DEMAND 181
11.3 TNF ALPHA 185
11.3.1 BIOSIMILAR ACCESS AND ENTRENCHED GUIDELINE USE TO SUSTAIN TNF ALPHA VOLUMES 185
11.4 CYTOKINE/INFLAMMATORY PATHWAY TARGETS 188
11.4.1 INTERLEUKIN AND INFLAMMATORY-PATHWAY EXPANSION TO DRIVE CHRONIC DISEASE ADOPTION 188
11.5 HER2 191
11.5.1 ADC INNOVATION AND BIOMARKER-LED EXPANSION TO STRENGTHEN HER2-TARGETED ANTIBODIES 191
11.6 OTHER TARGETS 194

12 ANTIBODY THERAPEUTICS MARKET, BY SOURCE 197
12.1 INTRODUCTION 198
12.2 HUMAN 198
12.2.1 LOWER IMMUNOGENICITY AND CHRONIC-USE EXPANSION TO SUPPORT FULLY HUMAN ANTIBODIES 198
12.3 HUMANIZED 202
12.3.1 LARGE BLOCKBUSTER BASE AND ENGINEERING FLEXIBILITY TO KEEP HUMANIZED ANTIBODIES DOMINANT 202
12.4 CHIMERIC 205
12.4.1 ESTABLISHED CLINICAL USE AND BIOSIMILAR ACCESS TO SUSTAIN CHIMERIC-ANTIBODY VOLUMES 205
12.5 OTHER SOURCES 208

13 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION 211
13.1 INTRODUCTION 212
13.2 INTRAVENOUS 212
13.2.1 COMPLEX ONCOLOGY AND HOSPITAL-BASED DOSING TO MAKE INTRAVENOUS ADMINISTRATION LARGEST ROUTE 212
13.3 SUBCUTANEOUS 216
13.3.1 LOWER ADMINISTRATION BURDEN AND HOME-CARE POTENTIAL TO MAKE SUBCUTANEOUS DELIVERY FASTEST-GROWING ROUTE 216
13.4 OTHER ROUTES OF ADMINISTRATION 219

14 ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA 222
14.1 INTRODUCTION 223
14.2 AUTOIMMUNE & INFLAMMATORY DISEASES 223
14.2.1 CHRONIC DISEASE BURDEN AND TARGETED BIOLOGIC SEQUENCING TO SUSTAIN DEMAND 223
14.3 ONCOLOGY 227
14.3.1 EARLIER-LINE IMMUNOTHERAPY, ADCS, AND BISPECIFICS TO BOOST MARKET GROWTH 227
14.4 HEMATOLOGY 230
14.4.1 DEEPENING RESPONSE EXPECTATIONS AND OUTPATIENT FORMATS TO ACCELERATE HEMATOLOGY ANTIBODY USE 230
14.5 INFECTIOUS DISEASES 233
14.5.1 LONG-ACTING PROPHYLAXIS AND PREPAREDNESS PROGRAMS TO SUPPORT MARKET GROWTH 233
14.6 BONE DISORDER 236
14.6.1 POPULATION AGING, FRACTURE PREVENTION, AND BIOSIMILAR ACCESS TO SUSTAIN DEMAND 236
14.7 IMMUNOLOGY 239
14.7.1 TYPE 2 DISEASE EXPANSION AND BIOMARKER-LED TREATMENT TO DRIVE GROWTH 239
14.8 NEUROLOGY 242
14.8.1 DISEASE-MODIFYING ANTIBODIES AND EASIER ADMINISTRATION TO MAKE NEUROLOGY HIGH-GROWTH AREA 242
14.9 OTHER THERAPEUTIC AREAS 245

15 ANTIBODY THERAPEUTICS MARKET, BY END USER 248
15.1 INTRODUCTION 249
15.2 HOSPITALS & SPECIALTY CARE CENTERS 249
15.2.1 COMPLEX INFUSION PROTOCOLS AND MULTIDISCIPLINARY CARE TO KEEP HOSPITALS AND SPECIALTY CENTERS DOMINANT 249
15.3 LONG-TERM CARE FACILITIES 253
15.3.1 AGING POPULATIONS AND SCHEDULED CHRONIC BIOLOGIC CARE TO SUPPORT GRADUAL LONG-TERM CARE ADOPTION 253
15.4 OTHER END USERS 256

16 ANTIBODY THERAPEUTICS MARKET, BY REGION 259
16.1 INTRODUCTION 260
16.2 NORTH AMERICA 260
16.2.1 US 267
16.2.1.1 Regulatory speed and high-value specialty care to drive market growth 267
16.2.2 CANADA 272
16.2.2.1 Public reimbursement and coordinated cancer care to support steady antibody adoption 272
16.3 EUROPE 277
16.3.1 GERMANY 282
16.3.1.1 AMNOG assessment and dense specialty networks to support high-value antibody use 282
16.3.2 UK 287
16.3.2.1 MHRA agility and NHS specialist pathways to sustain targeted antibody uptake 287
16.3.3 FRANCE 292
16.3.3.1 National HTA, oncology infrastructure, and biologics investment to support market growth 292
16.3.4 ITALY 297
16.3.4.1 AIFA monitoring and hospital oncology networks to enable controlled antibody expansion 297
16.3.5 SPAIN 302
16.3.5.1 Hospital pharmacy expertise and national positioning reports to support measured adoption 302
16.3.6 REST OF EUROPE 307
16.4 ASIA PACIFIC 312
16.4.1 CHINA 318
16.4.1.1 Domestic bispecific and ADC innovation to accelerate antibody market expansion 318
16.4.2 JAPAN 323
16.4.2.1 Universal coverage and first-in-class launches to support stable high-value adoption 323
16.4.3 SOUTH KOREA 328
16.4.3.1 Biologics manufacturing scale and biosimilar leadership to support rapid market development 328
16.4.4 INDIA 333
16.4.4.1 Cost-efficient biosimilars and expanding specialty care to broaden antibody access 333
16.4.5 AUSTRALIA 338
16.4.5.1 Specialist centers and efficient regulation to support adoption of differentiated antibodies 338
16.4.6 REST OF ASIA PACIFIC 343
16.5 LATIN AMERICA 348
16.5.1 BRAZIL 352
16.5.1.1 Large public and private care systems to anchor Latin American antibody demand 352
16.5.2 MEXICO 358
16.5.2.1 Large institutional purchasers and private oncology networks to support rising adoption 358
16.5.3 REST OF LATIN AMERICA 362
16.6 MIDDLE EAST 368
16.6.1 GCC COUNTRIES 372
16.6.1.1 Saudi Arabia 378
16.6.1.1.1 Vision 2030 investment and SFDA modernization to accelerate specialty-biologic access 378
16.6.1.2 UAE 383
16.6.1.2.1 Private insurance, medical hubs, and regulatory reforms to support premium antibody uptake 383
16.6.1.3 Rest of GCC Countries 388
16.6.2 REST OF MIDDLE EAST 392
16.7 AFRICA 396
16.7.1 BIOSIMILARS AND REGIONAL MANUFACTURING INITIATIVES OFFER A PATHWAY TO WIDER ACCESS 396

17 COMPETITIVE LANDSCAPE 402
17.1 INTRODUCTION 402
17.2 KEY STRATEGIES/RIGHT TO WIN 402
17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ANTIBODY THERAPEUTICS MARKET 402
17.3 REVENUE ANALYSIS, 2023–2025 404
17.4 MARKET SHARE ANALYSIS, 2025 404
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 406
17.5.1 STARS 406
17.5.2 EMERGING LEADERS 406
17.5.3 PERVASIVE PLAYERS 406
17.5.4 PARTICIPANTS 406
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 408
17.5.5.1 Company footprint 408
17.5.5.2 Region footprint 409
17.5.5.3 Format footprint 410
17.5.5.4 Source footprint 411
17.5.5.5 Route of administration footprint 412
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 413
17.6.1 PROGRESSIVE COMPANIES 413
17.6.2 RESPONSIVE COMPANIES 413
17.6.3 DYNAMIC COMPANIES 413
17.6.4 STARTING BLOCKS 413
17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 415
17.6.5.1 Detailed list of key startups/SMEs 415
17.6.5.2 Competitive benchmarking of key startups/SMEs 416
17.7 COMPANY VALUATION & FINANCIAL METRICS 417
17.7.1 COMPANY VALUATION 417
17.7.2 FINANCIAL METRICS 417
17.8 BRAND/PRODUCT COMPARISON 418
17.9 COMPETITIVE SCENARIOS 419
17.9.1 PRODUCT APPROVALS 419
17.9.2 DEALS 420
17.9.3 OTHER DEVELOPMENTS 420

18 COMPANY PROFILES 421
18.1 KEY PLAYERS 421
18.1.1 F. HOFFMANN-LA ROCHE LTD. 421
18.1.1.1 Business overview 421
18.1.1.2 Products offered 423
18.1.1.3 Recent developments 424
18.1.1.3.1 Product approvals 424
18.1.1.3.2 Deals 425
18.1.1.3.3 Expansions 426
18.1.1.4 MnM view 426
18.1.1.4.1 Key strengths 426
18.1.1.4.2 Strategic choices 426
18.1.1.4.3 Weaknesses & competitive threats 426
18.1.2 ABBVIE INC. 427
18.1.2.1 Business overview 427
18.1.2.2 Products offered 429
18.1.2.3 Recent developments 429
18.1.2.3.1 Product approvals 429
18.1.2.3.2 Deals 430
18.1.2.3.3 Expansions 431
18.1.2.4 MnM view 431
18.1.2.4.1 Key strengths 431
18.1.2.4.2 Strategic choices 431
18.1.2.4.3 Weaknesses & competitive threats 431
18.1.3 AMGEN INC. 432
18.1.3.1 Business overview 432
18.1.3.2 Products offered 434
18.1.3.3 Recent developments 434
18.1.3.3.1 Product approvals 434
18.1.3.3.2 Deals 435
18.1.3.3.3 Expansions 436
18.1.3.4 MnM view 436
18.1.3.4.1 Key strengths 436
18.1.3.4.2 Strategic choices 436
18.1.3.4.3 Weaknesses & competitive threats 436
18.1.4 REGENERON PHARMACEUTICALS, INC. 437
18.1.4.1 Business overview 437
18.1.4.2 Products offered 438
18.1.4.3 Recent developments 439
18.1.4.3.1 Product approvals 439
18.1.4.3.2 Deals 439
18.1.4.3.3 Expansions 440
18.1.4.4 MnM view 440
18.1.4.4.1 Key strengths 440
18.1.4.4.2 Strategic choices 440
18.1.4.4.3 Weaknesses & competitive threats 440
18.1.5 ASTRAZENECA PLC 441
18.1.5.1 Business overview 441
18.1.5.2 Products offered 442
18.1.5.3 Recent developments 443
18.1.5.3.1 Product approvals 443
18.1.5.3.2 Deals 443
18.1.5.3.3 Expansions 444
18.1.5.4 MnM view 444
18.1.5.4.1 Key strengths 444
18.1.5.4.2 Strategic choices 444
18.1.5.4.3 Weaknesses & competitive threats 444
18.1.6 BIOGEN INC. 445
18.1.6.1 Business overview 445
18.1.6.2 Products offered 447
18.1.6.3 Recent developments 447
18.1.6.3.1 Product approvals 447
18.1.6.3.2 Deals 448
18.1.6.3.3 Expansions 448
18.1.6.4 MnM view 449
18.1.6.4.1 Key strengths 449
18.1.6.4.2 Strategic choices 449
18.1.6.4.3 Weaknesses & competitive threats 449
18.1.7 MERCK & CO., INC. 450
18.1.7.1 Business overview 450
18.1.7.2 Products offered 451
18.1.7.3 Recent developments 452
18.1.7.3.1 Product approvals 452
18.1.7.3.2 Deals 452
18.1.7.4 MnM view 453
18.1.7.4.1 Key strengths 453
18.1.7.4.2 Strategic choices 453
18.1.7.4.3 Weaknesses & competitive threats 453
18.1.8 NOVARTIS AG 454
18.1.8.1 Business overview 454
18.1.8.2 Products offered 455
18.1.8.3 Recent developments 456
18.1.8.3.1 Product approvals 456
18.1.8.3.2 Deals 456
18.1.8.4 MnM view 456
18.1.8.4.1 Key strengths 456
18.1.8.4.2 Strategic choices 456
18.1.8.4.3 Weaknesses & competitive threats 456
18.1.9 DAIICHI SANKYO COMPANY, LIMITED 457
18.1.9.1 Business overview 457
18.1.9.2 Products offered 459
18.1.9.3 Recent developments 459
18.1.9.3.1 Product approvals 459
18.1.9.3.2 Deals 460
18.1.10 GSK PLC 461
18.1.10.1 Business overview 461
18.1.10.2 Products offered 462
18.1.10.3 Recent developments 463
18.1.10.3.1 Product approvals 463
18.1.11 SANOFI 464
18.1.11.1 Business overview 464
18.1.11.2 Products offered 465
18.1.11.3 Recent developments 466
18.1.11.3.1 Product approvals 466
18.1.11.3.2 Deals 466
18.1.12 GILEAD SCIENCES, INC. 467
18.1.12.1 Business overview 467
18.1.12.2 Products offered 468
18.1.12.3 Recent developments 469
18.1.12.3.1 Product approvals 469
18.1.13 JAZZ PHARMACEUTICALS PLC 470
18.1.13.1 Business overview 470
18.1.13.2 Products offered 471
18.1.13.3 Recent developments 472
18.1.13.3.1 Product approvals 472
18.1.13.3.2 Deals 472
18.1.14 PFIZER INC. 473
18.1.14.1 Business overview 473
18.1.14.2 Products offered 474
18.1.14.3 Recent developments 475
18.1.14.3.1 Product approvals 475
18.1.14.3.2 Deals 475
18.1.15 JOHNSON & JOHNSON 476
18.1.15.1 Business overview 476
18.1.15.2 Products offered 477
18.1.15.3 Recent developments 478
18.1.15.3.1 Product approvals 478
18.1.15.3.2 Deals 478
18.1.16 ELI LILLY AND COMPANY 479
18.1.16.1 Business overview 479
18.1.16.2 Products offered 480
18.1.16.3 Recent developments 481
18.1.16.3.1 Product approvals 481
18.1.16.3.2 Expansions 481
18.1.17 H. LUNDBECK A/S 482
18.1.17.1 Business overview 482
18.1.17.2 Products offered 483
18.1.17.3 Recent developments 483
18.1.17.3.1 Product approvals 483
18.2 OTHER PLAYERS 484
18.2.1 CHUGAI PHARMACEUTICAL CO., LTD. 484
18.2.2 AKESO, INC. 485
18.2.3 SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. 486
18.2.4 CELLTRION, INC. 488
18.2.5 CSL BEHRING 489
18.2.6 OTSUKA AMERICA PHARMACEUTICAL, INC. 490
18.2.7 LEPU BIOPHARMA CO., LTD. 491
18.2.8 SINOCELLTECH GROUP LTD. 492
18.2.9 SYNERMORE BIOLOGICS 493
18.2.10 SHANGHAI JUNSHI BIOSCIENCES CO., LTD. 494
18.2.11 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 495

19 RESEARCH METHODOLOGY 497
19.1 RESEARCH DATA 497
19.1.1 SECONDARY DATA 498
19.1.2 PRIMARY DATA 498
19.2 MARKET ESTIMATION METHODOLOGY 500
19.2.1 MARKET SIZE ESTIMATION 500
19.2.2 INSIGHTS FROM PRIMARY EXPERTS 502
19.2.3 BOTTOM-UP APPROACH 503
19.3 MARKET GROWTH RATE PROJECTIONS 504
19.4 MARKET BREAKDOWN & DATA TRIANGULATION 505
19.5 RESEARCH ASSUMPTIONS 506
19.6 RESEARCH LIMITATIONS 507
19.7 RISK ANALYSIS 507

20 APPENDIX 508
20.1 DISCUSSION GUIDE 508
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 513
20.3 CUSTOMIZATION OPTIONS 515
20.4 RELATED REPORTS 515
20.5 AUTHOR DETAILS 516

ページTOPに戻る

List of Tables/Graphs

FIGURE 1 ANTIBODY THERAPEUTICS MARKET SEGMENTATION & REGIONS COVERED 47.
FIGURE 2 ANTIBODY THERAPEUTICS MARKET: YEARS CONSIDERED 48.
FIGURE 3 MARKET SCENARIO 51.
FIGURE 4 GLOBAL ANTIBODY THERAPEUTICS MARKET, 2024–2035 52.
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIBODY THERAPEUTICS MARKET, 2023–2026 52.
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF ANTIBODY THERAPEUTICS MARKET 53.
FIGURE 7 HIGH-GROWTH SEGMENTS IN ANTIBODY THERAPEUTICS MARKET, 2026–2031 54.
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN ANTIBODY THERAPEUTICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 55.
FIGURE 9 RISING CLINICAL SUCCESS AND REGULATORY APPROVALS OF ANTIBODY THERAPEUTICS TO BOOST MARKET GROWTH 56.
FIGURE 10 INTRAVENOUS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE.
IN NORTH AMERICA IN 2025 57.
FIGURE 11 JAPAN TO REGISTER SIGNIFICANT CAGR DURING FORECAST PERIOD 58.
FIGURE 12 HUMANIZED ANTIBODIES TO DOMINATE MARKET DURING FORECAST PERIOD 58.
FIGURE 13 GLOBAL ANTIBODY THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 59.
FIGURE 14 GLOBAL ANTIBODY THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 65.
FIGURE 15 GLOBAL ANTIBODY THERAPEUTICS MARKET: VALUE CHAIN ANALYSIS 69.
FIGURE 16 GLOBAL ANTIBODY THERAPEUTICS MARKET: ECOSYSTEM ANALYSIS 71.
FIGURE 17 GLOBAL ANTIBODY THERAPEUTICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75.
FIGURE 18 IMPACT OF AI ON THE GLOBAL ANTIBODY THERAPEUTICS MARKET 86.
FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 100.
FIGURE 20 KEY BUYING CRITERIA, BY END USER 100.
FIGURE 21 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET SNAPSHOT 261.
FIGURE 22 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET SNAPSHOT 312.
FIGURE 23 REVENUE ANALYSIS OF KEY PLAYERS IN ANTIBODY THERAPEUTICS.
MARKET, 2023–2025 404.
FIGURE 24 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ANTIBODY THERAPEUTICS MARKET, 2025 405.
FIGURE 25 ANTIBODY THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX.
(KEY PLAYERS), 2025 407.
FIGURE 26 ANTIBODY THERAPEUTICS MARKET: COMPANY FOOTPRINT 408.
FIGURE 27 ANTIBODY THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 414.
FIGURE 28 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF.
KEY VENDORS 417.
FIGURE 29 EV/EBITDA OF KEY VENDORS 417.
FIGURE 30 ANTIBODY THERAPEUTICS MARKET: BRAND/PRODUCT COMPARISON 418.
FIGURE 31 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 422.
FIGURE 32 ABBVIE INC.: COMPANY SNAPSHOT (2025) 428.
FIGURE 33 AMGEN INC.: COMPANY SNAPSHOT (2025) 433.
FIGURE 34 REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025) 437.
FIGURE 35 ASTRAZENECA: COMPANY SNAPSHOT (2025) 441.
FIGURE 36 BIOGEN INC.: COMPANY SNAPSHOT (2025) 446.
FIGURE 37 MERCK & CO., INC.: COMPANY SNAPSHOT (2025) 451.
FIGURE 38 NOVARTIS AG: COMPANY SNAPSHOT (2025) 455.
FIGURE 39 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2025) 458.
FIGURE 40 GSK PLC: COMPANY SNAPSHOT (2025) 462.
FIGURE 41 SANOFI: COMPANY SNAPSHOT (2025) 465.
FIGURE 42 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2025) 468.
FIGURE 43 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2025) 471.
FIGURE 44 PFIZER INC.: COMPANY SNAPSHOT (2025) 474.
FIGURE 45 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2025) 477.
FIGURE 46 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2025) 480.
FIGURE 47 H. LUNDBECK A/S: COMPANY SNAPSHOT (2025) 482.
FIGURE 48 RESEARCH DESIGN 497.
FIGURE 49 ANTIBODY THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES 499.
FIGURE 50 ANTIBODY THERAPEUTICS MARKET SIZE ESTIMATION.
(SUPPLY-SIDE ANALYSIS), 2025 500.
FIGURE 51 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025 501.
FIGURE 52 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF.
F. HOFFMANN-LA ROCHE (2025) 501.
FIGURE 53 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 502.
FIGURE 54 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 503.
FIGURE 55 ANTIBODY THERAPEUTICS MARKET CAGR PROJECTIONS: 504.
FIGURE 56 DATA TRIANGULATION METHODOLOGY 506.
TABLE 1 ANTIBODY THERAPEUTICS MARKET: INCLUSIONS & EXCLUSIONS 48.
TABLE 2 GLOBAL ANTIBODY THERAPEUTICS MARKET: IMPACT ANALYSIS 60.
TABLE 3 GLOBAL ANTIBODY THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 66.
TABLE 4 GLOBAL ANTIBODY THERAPEUTICS MARKET: KEY ANTIBODY CDMOS/CMOS & SERVICE PROVIDERS 71.
TABLE 5 GLOBAL ANTIBODY THERAPEUTICS MARKET: MANUFACTURING SITES & CAPACITY EXPANSION OF KEY ANTIBODY MANUFACTURERS 72.
TABLE 6 AVERAGE SELLING PRICE OF KEY PRODUCTS, BY KEY PLAYER (2025) 73.
TABLE 7 INDICATIVE PRICE TREND DATA, BY PRODUCT (2023–2025) 73.
TABLE 8 AVERAGE SELLING PRICE OF KEY PRODUCTS, BY REGION (2025) 74.
TABLE 9 GLOBAL ANTIBODY THERAPEUTICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 & EVENTS, 2026–2027 74.
TABLE 10 GLOBAL ANTIBODY THERAPEUTICS MARKET: PIPELINE ANALYSIS 84.
TABLE 11 CASE STUDIES OF AI IMPLEMENTATION IN GLOBAL ANTIBODY.
THERAPEUTICS MARKET 87.
TABLE 12 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN GLOBAL ANTIBODY THERAPEUTICS MARKET 88.
TABLE 13 REGULATORY APPROVAL PATHWAYS, BY ANTIBODY FORMAT 89.
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 90.
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 91.
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 92.
TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 93.
TABLE 18 REIMBURSEMENT SCENARIO 94.
TABLE 19 COUNTRY-WISE REGULATORY SCENARIO FOR ANTIBODY THERAPEUTICS MANUFACTURERS 96.
TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 100.
TABLE 21 KEY BUYING CRITERIA, BY END USER 101.
TABLE 22 ANTIBODY THERAPEUTICS MARKET, BY PRODUCT, 2024–2035 (USD BILLION) 105.
TABLE 23 COMMERCIALIZED ANTIBODY PRODUCTS MARKET, BY REGION,.
2024–2035 (USD BILLION) 106.
TABLE 24 NORTH AMERICA: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 106.
TABLE 25 EUROPE: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 107.
TABLE 26 ASIA PACIFIC: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 107.
TABLE 27 LATIN AMERICA: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 108.
TABLE 28 MIDDLE EAST: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,.
BY REGION, 2024–2035 (USD BILLION) 108.
TABLE 29 GCC COUNTRIES: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 108.
TABLE 30 COMMERCIALIZED ANTIBODY PRODUCTS MARKET,.
BY TYPE, 2024–2035 (USD BILLION) 109.
TABLE 31 KEYTRUDA MARKET, BY REGION, 2024–2035 (USD BILLION) 110.
TABLE 32 NORTH AMERICA: KEYTRUDA MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 110.
TABLE 33 EUROPE: KEYTRUDA MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 111.
TABLE 34 ASIA PACIFIC: KEYTRUDA MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 111.
TABLE 35 LATIN AMERICA: KEYTRUDA MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 112.
TABLE 36 MIDDLE EAST: KEYTRUDA MARKET, BY REGION, 2024–2035 (USD BILLION) 112.
TABLE 37 GCC COUNTRIES: KEYTRUDA MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 112.
TABLE 38 DUPIXENT MARKET, BY REGION, 2024–2035 (USD BILLION) 113.
TABLE 39 NORTH AMERICA: DUPIXENT MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 113.
TABLE 40 EUROPE: DUPIXENT MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 114.
TABLE 41 ASIA PACIFIC: DUPIXENT MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 114.
TABLE 42 LATIN AMERICA: DUPIXENT MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 115.
TABLE 43 MIDDLE EAST: DUPIXENT MARKET, BY REGION, 2024–2035 (USD BILLION) 115.
TABLE 44 GCC COUNTRIES: DUPIXENT MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 115.
TABLE 45 SKYRIZI MARKET, BY REGION, 2024–2035 (USD BILLION) 116.
TABLE 46 NORTH AMERICA: SKYRIZI MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 116.
TABLE 47 EUROPE: SKYRIZI MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 117.
TABLE 48 ASIA PACIFIC: SKYRIZI MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 117.
TABLE 49 LATIN AMERICA: SKYRIZI MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 118.
TABLE 50 MIDDLE EAST: SKYRIZI MARKET, BY REGION, 2024–2035 (USD BILLION) 118.
TABLE 51 GCC COUNTRIES: SKYRIZI MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 118.
TABLE 52 DARZALEX MARKET, BY REGION, 2024–2035 (USD BILLION) 119.
TABLE 53 NORTH AMERICA: DARZALEX MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 119.
TABLE 54 EUROPE: DARZALEX MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 120.
TABLE 55 ASIA PACIFIC: DARZALEX MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 120.
TABLE 56 LATIN AMERICA: DARZALEX MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 121.
TABLE 57 MIDDLE EAST: DARZALEX MARKET, BY REGION, 2024–2035 (USD BILLION) 121.
TABLE 58 GCC COUNTRIES: DARZALEX MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 121.
TABLE 59 VYVGART MARKET, BY REGION, 2024–2035 (USD BILLION) 122.
TABLE 60 NORTH AMERICA: VYVGART MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 122.
TABLE 61 EUROPE: VYVGART MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 123.
TABLE 62 ASIA PACIFIC: VYVGART MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 123.
TABLE 63 LATIN AMERICA: VYVGART MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 124.
TABLE 64 MIDDLE EAST: VYVGART MARKET, BY REGION, 2024–2035 (USD BILLION) 124.
TABLE 65 GCC COUNTRIES: VYVGART MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 124.
TABLE 66 OTHER COMMERCIALIZED ANTIBODY PRODUCTS MARKET,.
BY REGION, 2024–2035 (USD BILLION) 125.
TABLE 67 NORTH AMERICA: OTHER COMMERCIALIZED ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 125.
TABLE 68 EUROPE: OTHER COMMERCIALIZED ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 126.
TABLE 69 ASIA PACIFIC: OTHER COMMERCIALIZED ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 126.
TABLE 70 LATIN AMERICA: OTHER COMMERCIALIZED ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 127.
TABLE 71 MIDDLE EAST: OTHER COMMERCIALIZED ANTIBODY PRODUCTS MARKET,.
BY REGION, 2024–2035 (USD BILLION) 127.
TABLE 72 GCC COUNTRIES: OTHER COMMERCIALIZED ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 127.
TABLE 73 PIPELINE ANTIBODY PRODUCTS MARKET, BY REGION, 2024–2035 (USD BILLION) 128.
TABLE 74 NORTH AMERICA: PIPELINE ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 128.
TABLE 75 EUROPE: PIPELINE ANTIBODY PRODUCTS MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 129.
TABLE 76 ASIA PACIFIC: PIPELINE ANTIBODY PRODUCTS MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 129.
TABLE 77 LATIN AMERICA: PIPELINE ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 130.
TABLE 78 MIDDLE EAST: PIPELINE ANTIBODY PRODUCTS MARKET,.
BY REGION, 2024–2035 (USD BILLION) 130.
TABLE 79 GCC COUNTRIES: PIPELINE ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 131.
TABLE 80 PIPELINE ANTIBODY PRODUCTS MARKET, BY TYPE, 2024–2035 (USD BILLION) 131.
TABLE 81 IVONESCIMAB MARKET, BY REGION, 2024–2035 (USD BILLION) 132.
TABLE 82 NORTH AMERICA: IVONESCIMAB MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 132.
TABLE 83 EUROPE: IVONESCIMAB MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 133.
TABLE 84 ASIA PACIFIC: IVONESCIMAB MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 133.
TABLE 85 LATIN AMERICA: IVONESCIMAB MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 134.
TABLE 86 MIDDLE EAST: IVONESCIMAB MARKET, BY REGION, 2024–2035 (USD BILLION) 134.
TABLE 87 GCC COUNTRIES: IVONESCIMAB MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 134.
TABLE 88 SACITUZUMAB TIRUMOTECAN (SAC-TMT) MARKET, BY REGION,.
2024–2035 (USD BILLION) 135.
TABLE 89 NORTH AMERICA: SACITUZUMAB TIRUMOTECAN (SAC-TMT) MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 135.
TABLE 90 EUROPE: SACITUZUMAB TIRUMOTECAN (SAC-TMT) MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 136.
TABLE 91 ASIA PACIFIC: SACITUZUMAB TIRUMOTECAN (SAC-TMT) MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 136.
TABLE 92 LATIN AMERICA: SACITUZUMAB TIRUMOTECAN (SAC-TMT) MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 137.
TABLE 93 MIDDLE EAST: SACITUZUMAB TIRUMOTECAN (SAC-TMT) MARKET,.
BY REGION, 2024–2035 (USD BILLION) 137.
TABLE 94 GCC COUNTRIES: SACITUZUMAB TIRUMOTECAN (SAC-TMT) MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 137.
TABLE 95 IZALONTAMAB BRENGITECAN MARKET, BY REGION, 2024–2035 (USD BILLION) 138.
TABLE 96 NORTH AMERICA: IZALONTAMAB BRENGITECAN MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 138.
TABLE 97 EUROPE: IZALONTAMAB BRENGITECAN MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 139.
TABLE 98 ASIA PACIFIC: IZALONTAMAB BRENGITECAN MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 139.
TABLE 99 LATIN AMERICA: IZALONTAMAB BRENGITECAN MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 140.
TABLE 100 MIDDLE EAST: IZALONTAMAB BRENGITECAN MARKET,.
BY REGION, 2024–2035 (USD BILLION) 140.
TABLE 101 GCC COUNTRIES: IZALONTAMAB BRENGITECAN MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 140.
TABLE 102 OTHER PIPELINE ANTIBODY PRODUCTS MARKET,.
BY REGION, 2024–2035 (USD BILLION) 141.
TABLE 103 NORTH AMERICA: OTHER PIPELINE ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 141.
TABLE 104 EUROPE: OTHER PIPELINE ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 142.
TABLE 105 ASIA PACIFIC: OTHER PIPELINE ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 142.
TABLE 106 LATIN AMERICA: OTHER PIPELINE ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 143.
TABLE 107 MIDDLE EAST: OTHER PIPELINE ANTIBODY PRODUCTS MARKET,.
BY REGION, 2024–2035 (USD BILLION) 143.
TABLE 108 GCC COUNTRIES: OTHER PIPELINE ANTIBODY PRODUCTS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 143.
TABLE 109 ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2024–2035 (USD BILLION) 145.
TABLE 110 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2024–2035 (USD BILLION) 146.
TABLE 111 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 146.
TABLE 112 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 147.
TABLE 113 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 147.
TABLE 114 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 148.
TABLE 115 MIDDLE EAST: MONOCLONAL ANTIBODIES MARKET, BY REGION,.
2024–2035 (USD BILLION) 148.
TABLE 116 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 148.
TABLE 117 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2024–2035 (USD BILLION) 149.
TABLE 118 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 149.
TABLE 119 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 150.
TABLE 120 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 150.
TABLE 121 LATIN AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 151.
TABLE 122 MIDDLE EAST: POLYCLONAL ANTIBODIES MARKET, BY REGION,.
2024–2035 (USD BILLION) 151.
TABLE 123 GCC COUNTRIES: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 151.
TABLE 124 ANTIBODY FRAGMENTS MARKET, BY REGION, 2024–2035 (USD BILLION) 152.
TABLE 125 NORTH AMERICA: ANTIBODY FRAGMENTS MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 152.
TABLE 126 EUROPE: ANTIBODY FRAGMENTS MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 153.
TABLE 127 ASIA PACIFIC: ANTIBODY FRAGMENTS MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 153.
TABLE 128 LATIN AMERICA: ANTIBODY FRAGMENTS MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 154.
TABLE 129 MIDDLE EAST: ANTIBODY FRAGMENTS MARKET, BY REGION,.
2024–2035 (USD BILLION) 154.
TABLE 130 GCC COUNTRIES: ANTIBODY FRAGMENTS MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 154.
TABLE 131 BISPECIFIC ANTIBODIES MARKET, BY REGION, 2024–2035 (USD BILLION) 155.
TABLE 132 NORTH AMERICA: BISPECIFIC ANTIBODIES MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 155.
TABLE 133 EUROPE: BISPECIFIC ANTIBODIES MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 156.
TABLE 134 ASIA PACIFIC: BISPECIFIC ANTIBODIES MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 156.
TABLE 135 LATIN AMERICA: BISPECIFIC ANTIBODIES MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 157.
TABLE 136 MIDDLE EAST: BISPECIFIC ANTIBODIES MARKET, BY REGION,.
2024–2035 (USD BILLION) 157.
TABLE 137 GCC COUNTRIES: BISPECIFIC ANTIBODIES MARKET, BY COUNTRY,.
2024–2035 (USD BILLION) 157.
TABLE 138 ANTIBODY-DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD BILLION) 158.
TABLE 139 NORTH AMERICA: ANTIBODY-DRUG CONJUGATES MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 158.
TABLE 140 EUROPE: ANTIBODY-DRUG CONJUGATES MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 159.
TABLE 141 ASIA PACIFIC: ANTIBODY-DRUG CONJUGATES MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 159.
TABLE 142 LATIN AMERICA: ANTIBODY-DRUG CONJUGATES MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 160.
TABLE 143 MIDDLE EAST: ANTIBODY-DRUG CONJUGATES MARKET,.
BY REGION, 2024–2035 (USD BILLION) 160.
TABLE 144 GCC COUNTRIES: ANTIBODY-DRUG CONJUGATES MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 160.
TABLE 145 ANTIBODY-DRUG CONJUGATES MARKET, BY PAYLOAD TYPE,.
2024–2035 (USD BILLION) 161.
TABLE 146 ANTIBODY-DRUG CONJUGATES MARKET FOR DM1 PAYLOAD,.
BY REGION, 2024–2035 (USD BILLION) 161.
TABLE 147 NORTH AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR DM1 PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 162.
TABLE 148 EUROPE: ANTIBODY-DRUG CONJUGATES MARKET FOR DM1 PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 162.
TABLE 149 ASIA PACIFIC: ANTIBODY-DRUG CONJUGATES MARKET FOR DM1 PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 163.
TABLE 150 LATIN AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR DM1 PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 163.
TABLE 151 MIDDLE EAST: ANTIBODY-DRUG CONJUGATES MARKET FOR DM1 PAYLOAD,.
BY REGION, 2024–2035 (USD BILLION) 164.
TABLE 152 GCC COUNTRIES: ANTIBODY-DRUG CONJUGATES MARKET FOR DM1 PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 164.
TABLE 153 ANTIBODY-DRUG CONJUGATES MARKET FOR MMAE PAYLOAD,.
BY REGION, 2024–2035 (USD BILLION) 165.
TABLE 154 NORTH AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR MMAE PAYLOAD, BY COUNTRY, 2024–2035 (USD BILLION) 165.
TABLE 155 EUROPE: ANTIBODY-DRUG CONJUGATES MARKET FOR MMAE PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 166.
TABLE 156 ASIA PACIFIC: ANTIBODY-DRUG CONJUGATES MARKET FOR MMAE PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 166.
TABLE 157 LATIN AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR MMAE PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 167.
TABLE 158 MIDDLE EAST: ANTIBODY-DRUG CONJUGATES MARKET FOR MMAE PAYLOAD,.
BY REGION, 2024–2035 (USD BILLION) 167.
TABLE 159 GCC COUNTRIES: ANTIBODY-DRUG CONJUGATES MARKET FOR MMAE PAYLOAD, BY COUNTRY, 2024–2035 (USD BILLION) 167.
TABLE 160 ANTIBODY-DRUG CONJUGATES MARKET FOR SN-38 PAYLOAD,.
BY REGION, 2024–2035 (USD BILLION) 168.
TABLE 161 NORTH AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR SN-38 PAYLOAD, BY COUNTRY, 2024–2035 (USD BILLION) 168.
TABLE 162 EUROPE: ANTIBODY-DRUG CONJUGATES MARKET FOR SN-38 PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 169.
TABLE 163 ASIA PACIFIC: ANTIBODY-DRUG CONJUGATES MARKET FOR SN-38 PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 169.
TABLE 164 LATIN AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR SN-38 PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 170.
TABLE 165 MIDDLE EAST: ANTIBODY-DRUG CONJUGATES MARKET FOR SN-38 PAYLOAD,.
BY REGION, 2024–2035 (USD BILLION) 170.
TABLE 166 GCC COUNTRIES: ANTIBODY-DRUG CONJUGATES MARKET FOR SN-38 PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 170.
TABLE 167 ANTIBODY-DRUG CONJUGATES MARKET FOR DM4 PAYLOAD,.
BY REGION, 2024–2035 (USD BILLION) 171.
TABLE 168 NORTH AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR DM4 PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 171.
TABLE 169 EUROPE: ANTIBODY-DRUG CONJUGATES MARKET FOR DM4 PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 172.
TABLE 170 ASIA PACIFIC: ANTIBODY-DRUG CONJUGATES MARKET FOR DM4 PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 172.
TABLE 171 LATIN AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR DM4 PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 173.
TABLE 172 MIDDLE EAST: ANTIBODY-DRUG CONJUGATES MARKET FOR DM4 PAYLOAD,.
BY REGION, 2024–2035 (USD BILLION) 173.
TABLE 173 GCC COUNTRIES: ANTIBODY-DRUG CONJUGATES MARKET FOR DM4 PAYLOAD,.
BY COUNTRY, 2024–2035 (USD BILLION) 173.
TABLE 174 ANTIBODY-DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES,.
BY REGION, 2024–2035 (USD BILLION) 174.
TABLE 175 NORTH AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2024–2035 (USD BILLION) 174.
TABLE 176 EUROPE: ANTIBODY-DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES,.
BY COUNTRY, 2024–2035 (USD BILLION) 175.
TABLE 177 ASIA PACIFIC: ANTIBODY-DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2024–2035 (USD BILLION) 175.
TABLE 178 LATIN AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2024–2035 (USD BILLION) 176.
TABLE 179 MIDDLE EAST: ANTIBODY-DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY REGION, 2024–2035 (USD BILLION) 176.
TABLE 180 GCC COUNTRIES: ANTIBODY-DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2024–2035 (USD BILLION) 176.
TABLE 181 OTHER ANTIBODY THERAPEUTICS MARKET, BY REGION,.
2024–2035 (USD BILLION) 177.
TABLE 182 NORTH AMERICA: OTHER ANTIBODY THERAPEUTICS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 177.
TABLE 183 EUROPE: OTHER ANTIBODY THERAPEUTICS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 178.
TABLE 184 ASIA PACIFIC: OTHER ANTIBODY THERAPEUTICS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 178.
TABLE 185 LATIN AMERICA: OTHER ANTIBODY THERAPEUTICS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 179.
TABLE 186 MIDDLE EAST: OTHER ANTIBODY THERAPEUTICS MARKET,.
BY REGION, 2024–2035 (USD BILLION) 179.
TABLE 187 GCC COUNTRIES: OTHER ANTIBODY THERAPEUTICS MARKET,.
BY COUNTRY, 2024–2035 (USD BILLION) 179.
TABLE 188 ANTIBODY THERAPEUTICS MARKET, BY TARGET, 2024–2035 (USD BILLION) 181.
TABLE 189 ANTIBODY THERAPEUTICS MARKET FOR PD-1/PD-L1 TARGETS,.
BY REGION, 2024–2035 (USD BILLION) 182.
TABLE 190 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR PD-1/PD-L1 TARGETS, BY COUNTRY, 2024–2035 (USD BILLION) 182.
TABLE 191 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR PD-1/PD-L1 TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 183.
TABLE 192 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR PD-1/PD-L1 TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 183.
TABLE 193 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR PD-1/PD-L1 TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 184.
TABLE 194 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR PD-1/PD-L1 TARGETS,.
BY REGION, 2024–2035 (USD BILLION) 184.
TABLE 195 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR PD-1/PD-L1 TARGETS, BY COUNTRY, 2024–2035 (USD BILLION) 184.
TABLE 196 ANTIBODY THERAPEUTICS MARKET FOR TNF ALPHA TARGETS,.
BY REGION, 2024–2035 (USD BILLION) 185.
TABLE 197 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR TNF ALPHA TARGETS, BY COUNTRY, 2024–2035 (USD BILLION) 185.
TABLE 198 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR TNF ALPHA TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 186.
TABLE 199 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR TNF ALPHA TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 186.
TABLE 200 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR TNF ALPHA TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 187.
TABLE 201 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR TNF ALPHA TARGETS,.
BY REGION, 2024–2035 (USD BILLION) 187.
TABLE 202 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR TNF ALPHA TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 187.
TABLE 203 ANTIBODY THERAPEUTICS MARKET FOR CYTOKINE/INFLAMMATORY PATHWAY TARGETS, BY REGION, 2024–2035 (USD BILLION) 188.
TABLE 204 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR CYTOKINE/INFLAMMATORY PATHWAY TARGETS, BY COUNTRY,.
2024–2035 (USD BILLION) 188.
TABLE 205 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR CYTOKINE/INFLAMMATORY PATHWAY TARGETS, BY COUNTRY, 2024–2035 (USD BILLION) 189.
TABLE 206 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR CYTOKINE/INFLAMMATORY PATHWAY TARGETS, BY COUNTRY, 2024–2035 (USD BILLION) 189.
TABLE 207 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR CYTOKINE/INFLAMMATORY PATHWAY TARGETS, BY COUNTRY,.
2024–2035 (USD BILLION) 190.
TABLE 208 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR CYTOKINE/INFLAMMATORY PATHWAY TARGETS, BY REGION, 2024–2035 (USD BILLION) 190.
TABLE 209 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR CYTOKINE/INFLAMMATORY PATHWAY TARGETS, BY COUNTRY,.
2024–2035 (USD BILLION) 190.
TABLE 210 ANTIBODY THERAPEUTICS MARKET FOR HER2 TARGETS,.
BY REGION, 2024–2035 (USD BILLION) 191.
TABLE 211 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HER2 TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 191.
TABLE 212 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HER2 TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 192.
TABLE 213 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HER2 TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 192.
TABLE 214 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HER2 TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 193.
TABLE 215 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR HER2 TARGETS,.
BY REGION, 2024–2035 (USD BILLION) 193.
TABLE 216 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR HER2 TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 193.
TABLE 217 ANTIBODY THERAPEUTICS MARKET FOR OTHER TARGETS,.
BY REGION, 2024–2035 (USD BILLION) 194.
TABLE 218 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 194.
TABLE 219 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 195.
TABLE 220 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 195.
TABLE 221 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 196.
TABLE 222 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR OTHER TARGETS,.
BY REGION, 2024–2035 (USD BILLION) 196.
TABLE 223 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR OTHER TARGETS,.
BY COUNTRY, 2024–2035 (USD BILLION) 196.
TABLE 224 ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2024–2035 (USD BILLION) 198.
TABLE 225 ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES,.
BY REGION, 2024–2035 (USD BILLION) 199.
TABLE 226 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 199.
TABLE 227 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 200.
TABLE 228 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 200.
TABLE 229 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 201.
TABLE 230 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES,.
BY REGION, 2024–2035 (USD BILLION) 201.
TABLE 231 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 201.
TABLE 232 ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES,.
BY REGION, 2024–2035 (USD BILLION) 202.
TABLE 233 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2024–2035 (USD BILLION) 202.
TABLE 234 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 203.
TABLE 235 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 203.
TABLE 236 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2024–2035 (USD BILLION) 204.
TABLE 237 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES,.
BY REGION, 2024–2035 (USD BILLION) 204.
TABLE 238 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2024–2035 (USD BILLION) 204.
TABLE 239 ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES,.
BY REGION, 2024–2035 (USD BILLION) 205.
TABLE 240 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 205.
TABLE 241 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 206.
TABLE 242 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 206.
TABLE 243 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 207.
TABLE 244 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES,.
BY REGION, 2024–2035 (USD BILLION) 207.
TABLE 245 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 207.
TABLE 246 ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES,.
BY REGION, 2024–2035 (USD BILLION) 208.
TABLE 247 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 208.
TABLE 248 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 209.
TABLE 249 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 209.
TABLE 250 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 210.
TABLE 251 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES,.
BY REGION, 2024–2035 (USD BILLION) 210.
TABLE 252 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES,.
BY COUNTRY, 2024–2035 (USD BILLION) 210.
TABLE 253 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION,.
2024–2035 (USD BILLION) 212.
TABLE 254 ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2024–2035 (USD BILLION) 213.
TABLE 255 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 213.
TABLE 256 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 214.
TABLE 257 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 214.
TABLE 258 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 215.
TABLE 259 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2024–2035 (USD BILLION) 215.
TABLE 260 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 215.
TABLE 261 ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2024–2035 (USD BILLION) 216.
TABLE 262 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 216.
TABLE 263 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 217.
TABLE 264 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 217.
TABLE 265 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 218.
TABLE 266 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2024–2035 (USD BILLION) 218.
TABLE 267 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 218.
TABLE 268 ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION,.
BY REGION, 2024–2035 (USD BILLION) 219.
TABLE 269 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 219.
TABLE 270 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 220.
TABLE 271 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 220.
TABLE 272 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 221.
TABLE 273 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2024–2035 (USD BILLION) 221.
TABLE 274 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 221.
TABLE 275 ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,.
2024–2035 (USD BILLION) 223.
TABLE 276 ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2024–2035 (USD BILLION) 224.
TABLE 277 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2024–2035 (USD BILLION) 224.
TABLE 278 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2024–2035 (USD BILLION) 225.
TABLE 279 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2024–2035 (USD BILLION) 225.
TABLE 280 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2024–2035 (USD BILLION) 226.
TABLE 281 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2024–2035 (USD BILLION) 226.